CN102993205B - High-yield purification method for preparation of high-purity sildenafil freebases - Google Patents

High-yield purification method for preparation of high-purity sildenafil freebases Download PDF

Info

Publication number
CN102993205B
CN102993205B CN201210581758.XA CN201210581758A CN102993205B CN 102993205 B CN102993205 B CN 102993205B CN 201210581758 A CN201210581758 A CN 201210581758A CN 102993205 B CN102993205 B CN 102993205B
Authority
CN
China
Prior art keywords
toluene
free base
methanol
sildenafil
sildenafil free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210581758.XA
Other languages
Chinese (zh)
Other versions
CN102993205A (en
Inventor
刘沫毅
刘清梁
李继斌
李志强
祈伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Resources Saike Pharmaceutical Co Ltd
Original Assignee
China Resources Saike Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Resources Saike Pharmaceutical Co Ltd filed Critical China Resources Saike Pharmaceutical Co Ltd
Priority to CN201210581758.XA priority Critical patent/CN102993205B/en
Publication of CN102993205A publication Critical patent/CN102993205A/en
Application granted granted Critical
Publication of CN102993205B publication Critical patent/CN102993205B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of medicinal chemistry, relates to a purification method for high-purity sildenafil freebases, particularly to a purification method for removing new impurities from the sildenafil freebases. The method includes adding 1-6 times (v/w) of organic solvents to sildenafil freebase (II) crude products, stirring fully, warming to 40-60DEG C, stirring for 1-6h with temperature preservation, then cooling to the room temperature, filtering and drying to obtain sildenafil freebase (II) fine products.

Description

Purification method for preparing high-purity sildenafil free base with high yield
Technical Field
The invention belongs to the technical field of pharmaceutical chemistry, and relates to a method for purifying sildenafil free alkali, in particular to a purification method for removing new impurities from sildenafil free alkali.
Background
Sildenafil citrate, marketed under the trade name Viagra, by Pesper USA in 1997, under the chemical name 5- [ (2-ethoxy-5 (-4-methylpiperazine-1-sulfonyl) phenyl ] -1-methyl-3-n-propyl-1, 6-dihydro-7H-pyrazolo [ 4, 3-d ] pyrimidin-7-one, is mainly used clinically for the treatment of sexual dysfunction. The action mechanism is to inhibit the activity of phosphodiesterase V, prevent cGMP and cAMP from being hydrolyzed to generate corresponding 5-nucleotide monophosphate, improve the concentration of cGMP between tissues, inhibit the relaxation of smooth muscle and achieve the purpose of treatment.
The patent of sildenafil citrate compound has expired so far, but the american pfeiffer company has patented the indication of sildenafil for treating ED (10/22/2019), so that the company manufactures wanaike with sildenafil citrate, which is the only drug currently on the market legally with sildenafil as a main ingredient.
Similarly, the only commercial pharmaceutical product for the legal production of sildenafil citrate is the fevered company in the united states, and the main industrial process routes reported by the commercial pharmaceutical product mainly include two types according to the sequence of pyrimidine cyclization and sulfonyl chlorination (Peter, Gree chem., 2004, 6, 43-48).
1. Pyrimidine cyclization was preceded and sulfonyl chlorination was followed (see patent US 5250534, buffere corporation, 1992). The method comprises the steps of condensing o-ethoxybenzoyl chloride (VI) and 4-amino-1-methyl-3-n-propylpyrazole-5-formamide (VII), cyclizing, sulfonating, aminating, and salifying to obtain sildenafil citrate. The yields of the condensation reaction and the sulphonamide reaction are respectively only 40 percent and 49 percent, and the condensation product and the cyclization product need to be separated by column chromatography, so the total yield of the whole route is low and the material consumption is high. After the process of the company is improved, the total yield is improved to 35.9 percent from the original 9.8 percent (calculated by taking a key intermediate VII as a reference), and the method is suitable for industrial production. At present, the route has no legal problems such as patent protection and the like, and the raw material medicine can be researched and declared to be produced in China. The synthetic route is as follows:
2. sulfonyl chlorination precedes pyrimidine cyclization (see patent US5955611, Calif., 1997). According to the method, o-ethoxybenzoic acid (VIII) is used as a raw material, and is subjected to sulfonylchlorination and sulfonylamination reactions, then is subjected to condensation reaction with a key intermediate (VII), then is subjected to cyclization reaction, and finally is salified to obtain sildenafil citrate, wherein the total yield of the process is 75% (both calculated by taking the key intermediate VII as a reference). The synthetic route is as follows:
in combination with the actual legal state of the patent, we have conducted quality studies on the two processes in turn.
Firstly, after a large number of quality research experiments on the improved process (1994, Perey company, USA) of US 5250534, we surprisingly found that in the process route, a new impurity (I08) is found in the compounds (I) to (IV), and the content of the impurity is varied from 0.02 to 2%. And then, by column chromatography separation and combination of spectrograms such as high resolution mass spectrum and nuclear magnetic resonance, the structural formula of the new impurity (I08) is determined as follows:
the research on the impurity source finds that the new impurity I08 is formed in two ways:
1) the subsequent reaction of the impurities carried by the material o-acetoxybenzoyl chloride (VI) is shown as the synthetic route in the method 1.
2) The synthesis route of the reaction Intermediate (IV) as a by-product of sulfonyl chlorination is shown in method 2.
The impurity I08 generated by the method 2 has little polarity difference with the Intermediate (IV), is not easy to be refined and removed, and generally has the content of 0.1-1.5%. The accumulation of impurity I08 by the sulfonyl chloride reaction brings sildenafil free
The content of the crude product of the alkali (II) is generally 0.1-2% according to the different taking-out modes of the crude product.
The method comprises the following steps:
the method 2 comprises the following steps:
then, we also studied the second preparation process route involved in US5955611, and found a new impurity I08 with a content of 0.02-0.5% in the process of (XI) carrying out cyclization reaction to prepare sildenafil free base (II), and the synthetic route is as follows:
at present, no new impurity I08 of sildenafil free base is reported in the literature, and no method for removing the impurity is described in the literature.
In addition, it was found that, because of the large difference in polarity between (II) and I08, the new impurity I08 was relatively easy to purify as the free base; further tests have shown that subsequent purification after salt formation is difficult to remove if the free base is not purified below acceptable limits.
Meanwhile, the existing USP and EP quality standards adopt an isocratic analysis method, the impurity cannot be detected, and a purification method is very necessary to be determined on the quality control of sildenafil free base, so that the content of the impurity is ensured to be not more than 0.1%.
The invention content is as follows:
the invention aims to provide a method for purifying sildenafil free base.
The purification method of the invention is to remove the impurity I08 from the crude sildenafil free base (II) to obtain a fine sildenafil free base product with high purity and high yield.
Specifically, the purification method comprises the following steps: placing the crude product of the sildenafil free base (II) into a reaction bottle, adding 1-6 times (v/w) of organic solvent, fully stirring, heating to 40-60 ℃, preserving heat, stirring for 1-6h, cooling to room temperature, filtering, and drying to obtain the fine product of the sildenafil free base (II).
Preferably, the purification method of the present invention comprises the steps of: placing the crude product of the sildenafil free base (II) into a reaction bottle, adding 2-4 times (v/w) of organic solvent, fully stirring, heating to 40-50 ℃, preserving heat, stirring for 2-4h, cooling to room temperature, filtering, and drying to obtain the fine product of the sildenafil free base (II).
Wherein the organic solvent is selected from: one or more of toluene, xylene, acetone, butanone, methanol and ethanol. Preferred organic solvents are toluene, xylene, a mixed solvent of toluene and xylene, and a mixed solvent of toluene and methanol. The volume percentage of the methanol in the mixed solvent of the toluene and the methanol is 5-30%, and the volume percentage of the toluene in the mixed solvent of the toluene and the xylene is 10-30%. Further preferably, the volume percentage of the methanol in the mixed solvent of the toluene and the methanol is 10-20%, and the volume percentage of the toluene in the mixed solvent of the toluene and the xylene is 10-20%.
The content of impurity I08 in the refined sildenafil free alkali (II) is not more than 0.1 percent,
the content of the impurity I08 in the refined sildenafil free alkali (II) is controlled to be 0.025-0.058%.
The crude sildenafil free base (II) of the present invention can be either commercially available or prepared by methods known in the art.
The preparation process route (refer to US 5250534 and optimized) of the crude sildenafil free alkali (II) (the purity of the pure product is more than 95 percent and the impurity I08 is 0.5-2 percent) is as follows:
a) 4-amino-1-methyl-3-n-propyl pyrazole-5-formamide (VII) and o-acetoxybenzoyl chloride (VI) are subjected to condensation reaction in dichloromethane and under the condition of triethylamine acid-binding agent, and then refined to obtain an intermediate (V).
b) And (3) carrying out cyclization reaction on the intermediate (V) in alcohol and strong alkali, and regulating the pH value to obtain an Intermediate (IV).
c) And (3) carrying out sulfonyl chlorination on the Intermediate (IV) in a chlorosulfonic acid system, and carrying out post-treatment by adopting dichloromethane and water to obtain an intermediate (III).
d) And (3) performing sulfonylation amination reaction on the intermediate (III) and N-methylpiperazine in ethanol, and obtaining a sildenafil free base (II) crude product through concentration and pH regulation.
Wherein,
a) in the step, the content of the impurity I08 in the Intermediate (IV) is directly influenced by different refined solvents, but the selectable organic solvents comprise toluene, xylene, ethyl acetate, isopropyl acetate, methanol, ethanol, isopropanol, acetone, butanone, tetrahydrofuran, dioxane and the like.
b) In the step, the alcohol can be methanol, ethanol, isopropanol, tert-butanol and the like; the strong base includes inorganic strong bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide and the like, and organic strong bases such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like. The content of an impurity I08 in the Intermediate (IV) obtained by post-treatment is 0.1-1%.
c) In the step, the feeding molar ratio of the chlorosulfonic acid is at least 10 times of the molar number of the Intermediate (IV), so that the reaction is ensured to be sufficient. The content of the impurity I08 in the intermediate (III) obtained by post-treatment is 0.1-1.5%.
d) In the step, a crude product of sildenafil free base (II) is obtained after simple reaction treatment, wherein the content of impurity I08 is 0.1-1.5%.
According to the invention, a large number of purification experiments show that when the impurity content of the crude product of the sildenafil free base (II) is within 0.5%, the crude product of the sildenafil free base (II) can be directly obtained at one time by adopting organic solvents including aromatic hydrocarbon compounds such as toluene and xylene, ketone solvents such as acetone and butanone, alcohols such as methanol and ethanol, or the solvent mixed solution, wherein the content of the impurity I08 is not more than 0.1%, and then the impurity I08 is directly controlled to be below an acceptable limit through salt formation.
When the impurity content of the crude product of the sildenafil free base (II) is 0.5-2%, the content of the impurity I08 in a common solvent can be controlled to be not more than 0.1% by purifying and refining for many times (namely more than two times).
Wherein, the high yield refers to the yield of more than 90 percent.
Wherein "high purity" means greater than 99% purity by HPLC.
Wherein the room temperature is 20-30 ℃.
According to the invention, through selection of different solvents, several solvents such as toluene, methanol and a mixed solvent (Smix) thereof, particularly a mixed solvent of toluene and methanol, can be found, the content of the impurity I08 can be well controlled to be not more than 0.1% at one time, the purity of the refined sildenafil free base (II) is more than 99%, and the yield is more than 90%. The refined free base product obtained by the method can be directly salified, and a high-quality sildenafil finished product (wherein the content of the impurity I08 is below 0.02%) with the content of more than 99.5% can be obtained without refining.
In the invention, the sildenafil free alkali (II) crude product is self-made (II) with the purity of more than 95% and the content of impurity I08 of 0.5-2%.
Another object of the present invention is to provide a method for detecting sildenafil.
Wherein, the chromatographic conditions are as follows:
A. a chromatographic column: c18Column, Waters Spherisorb ODS 14.6X 250mm 5 μm;
B. mobile phase A: 0.05mol/L triethylamine phosphate solution (7 ml of triethylamine, 1000ml of water, pH adjusted to 3.0 with phosphoric acid) -methanol-acetonitrile (58: 25: 17);
mobile phase B: 0.05mol/L triethylamine phosphate solution (7 ml of triethylamine, 1000ml of water and phosphoric acid for adjusting the pH value to 3.0) -acetonitrile (30: 70);
C. mobile phase gradient procedure
D. Detection wavelength: 290 nm;
E. column temperature: 30 ℃;
F. sample introduction amount: 20 mu l of the mixture;
G. flow rate: 1 ml/min;
H. operating time: 60 min;
the HPLC chromatogram of the refined sildenafil free base (II) (wherein the retention time of 46.392min is the chromatographic peak of impurity I08) is shown in figure 1.
Drawings
FIG. 1 shows HPLC chromatogram of fine sildenafil free base (II)
Detailed Description
The following examples are intended to be illustrative of the present invention and should not be construed as limiting the present patent.
EXAMPLE 1 preparation of crude sildenafil free base (II)
Wherein, the 4-amino-1-methyl-3-n-propyl pyrazole-5-formamide (VII) is from thoroughfare state Yongchu chemical technology Co., Ltd, the o-ethoxybenzoyl chloride (VI) is from Ziboyixin chemical industry Co., Ltd, and other reagents are from Beijing chemical reagent Co., Ltd of the national medicine group.
1) Synthesis of 1-methyl-3-propyl-4- (2-ethoxybenzamido) pyrazole-5-carboxamide (V)
Adding 500ml of dichloromethane into a 2L reaction bottle, then adding 100g of (VII), starting stirring, then adding 83g of triethylamine, then cooling to 0 ℃ in a low-temperature bath, dropwise adding 110g of (VI), keeping the temperature at room temperature for reacting for 4h after the dropwise adding is finished, then adding water for washing for 1 time, standing and separating, directly and averagely dividing the obtained dichloromethane layer into two parts, concentrating and evaporating to dryness.
The method A comprises the following steps: refining 100ml ethyl acetate, filtering and drying to obtain 75g (V)AThe yield thereof was found to be 83%.
The method B comprises the following steps: refining 100ml ethanol, filtering, drying to obtain 60g (V)BThe yield thereof was found to be 66%.
2) Synthesis of 1-methyl-3-propyl-5- (2-ethoxy) phenyl-6, 7-dihydro-1H-pyrazolo [ 4, 3-d ] pyrimidin-7-one (IV)
Adding 180mL of methanol and 10g of sodium hydroxide into a 1L reaction bottle, then adding 60g of (V), heating to reflux reaction for 3h, concentrating and evaporating to dryness, adding 100mL of water, cooling to room temperature, adjusting pH to be neutral by using 2N hydrochloric acid, filtering, and drying to obtain about 50g of (IV), wherein the yield is 88.8%.
The method A comprises the following steps: adopt (V)AAs raw materials, de (IV)AWherein the content of the impurity I08 is 0.85 percent.
The method B comprises the following steps: adopt (V)BAs raw materials, de (IV)BWherein the content of the impurity I08 is 0.18 percent.
3) Synthesis of 1-methyl-3-propyl-5- (2-ethoxy-5-chlorosulfonyl) phenyl-6, 7-dihydro-1H-pyrazolo [ 4, 3-d ] pyrimidin-7-one (III)
160ml of chlorosulfonic acid is added into a 1L reaction bottle, then the bottle is cooled to below 0 ℃ in a low-temperature bath, 40g of (IV) is added, and after the addition is finished, the bottle is reacted at room temperature for more than 4 hours. The reaction mixture was slowly added to a 2L reaction flask containing a prepared mixture of 600mL of ice water and 400mL of methylene chloride, and the resulting methylene chloride layer was washed with salt, dried over anhydrous sodium sulfate, filtered, and distilled to obtain about 36g of a product (III) with a yield of 68.7%.
The method A comprises the following steps: adopt (IV)AAs raw materials, de (III)AWherein the content of the impurity I08 is 1.24 percent.
The method B comprises the following steps: adopt (IV)BAs raw materials, de (III)BWherein the content of the impurity I08 is 0.52 percent.
4): synthesis of 1-methyl-3-propyl-5- [ (2-ethoxy-5- (4-methylpiperazine-1-sulfonyl) phenyl ] -6, 7-dihydro-1H-pyrazolo [ 4, 3-d ] pyrimidin-7-one (II)
Pumping 360mL of ethanol into a 1L reaction bottle, adding 36g (III), fully stirring, adding N-methyl piperazine, reacting at room temperature for 3 hours, distilling and concentrating the ethanol, adding 500mL of water, adjusting pH to be neutral by 10% potassium carbonate, filtering, and drying to obtain 39.5g of a product (II), wherein the yield is 95%.
The method A comprises the following steps: adopt (IV)AAs raw material, obtain crude product (II)AWherein the content of the impurity I08 is 1.28 percent, and the purity is 95.4 percent.
The method B comprises the following steps: adopt (IV)BAs raw material, obtain crude product (II)BWherein the content of the impurity I08 is 0.54 percent, and the purity is 96.3 percent.
EXAMPLE 2 preparation of a Fine product of sildenafil free base (II)
Adding 15ml of toluene and 2ml of methanol into a 100ml reaction bottle, adding 5g of crude sildenafil free base (II), fully stirring, heating to 45-50 ℃, keeping the temperature, stirring for 2h, cooling to room temperature, filtering, and drying to obtain the product (II).
The method A comprises the following steps: the yield is 92.8 percent, wherein the content of the impurity I08 is 0.058 percent
The method B comprises the following steps: the yield is 93.4%, wherein the content of the impurity I08 is 0.028%
EXAMPLE 3 preparation of a Fine product of sildenafil free base (II)
Adding 15ml of toluene and 4ml of methanol into a 100ml reaction bottle, adding 5g of crude sildenafil free base (II), fully stirring, heating to 45-50 ℃, keeping the temperature, stirring for 2h, cooling to room temperature, filtering, and drying to obtain the product (II).
The method A comprises the following steps: the yield is 90.6 percent, wherein the content of the impurity I08 is 0.054 percent
The method B comprises the following steps: the yield is 91.2 percent, wherein the content of the impurity I08 is 0.025 percent
Example 4 solvent screening procedure for preparation of fine sildenafil free base (II)
And (3) adding 5ml of solvent into a 50ml reaction bottle, adding 1g of crude sildenafil free base (II), fully stirring, heating to 45-50 ℃, keeping the temperature, stirring for 2 hours, cooling to room temperature, filtering, and drying to obtain the product (II).
The results are as follows:
the single solvent experiment results show that: when toluene or xylene is selected as a single solvent, the product yield is highest, the effect of removing the impurity I08 is achieved, the purification effect of methanol, toluene, xylene, ethanol, acetone and butanone is best, and the obtained purity is highest.
The mixed solvent has the following specific results:
the experimental results show that: toluene and methanol are selected as mixed solvents, the yield is not much different from toluene or xylene, but the content of the impurity I08 is the least, the control is easy, and the purification effect is better than that of a single solvent and other mixed solvents. Meanwhile, when the methanol ratio is excessively increased, the purity is increased, but the yield is remarkably decreased.
Experiments show that the organic solvent is preferably toluene, xylene, a mixed solvent of toluene and xylene, and a mixed solution of toluene and methanol, wherein in the solution of toluene and methanol, the proportion of methanol needs to be controlled, and is 5-30%, preferably 10-20%.

Claims (7)

1. A process for the purification of sildenafil free base comprising the steps of: taking the crude product of the sildenafil free alkali (II), adding 1-6 times (v/w) of organic solvent, fully stirring, heating to 40-60 ℃, keeping the temperature and stirring for 1-6h, then cooling to room temperature, filtering, drying to obtain the fine product of the sildenafil free alkali (II),
wherein the organic solvent is selected from: toluene, xylene, a mixed solvent of toluene and methanol,
wherein the content of the impurity I08 in the refined sildenafil free base (II) is not more than 0.1 percent,
2. the purification method according to claim 1, characterized in that it comprises the following steps: taking the crude product of the sildenafil free base (II), adding 2-4 times (v/w) of organic solvent, fully stirring, heating to 40-50 ℃, keeping the temperature, stirring for 2-4h, cooling to room temperature, filtering, and drying to obtain the fine product of the sildenafil free base (II).
3. The purification method according to claim 1, wherein the volume percentage of methanol in the mixed solvent of toluene and methanol is 5 to 30%, and the volume percentage of toluene in the mixed solvent of toluene and xylene is 10 to 30%.
4. The purification method according to claim 1, wherein the volume percentage of methanol in the mixed solvent of toluene and methanol is 10 to 20%, and the volume percentage of toluene in the mixed solvent of toluene and xylene is 10 to 20%.
5. The purification process according to claim 1, wherein the content of impurity I08 in the fine sildenafil free base (II) is controlled to be 0.025% to 0.058%.
6. The purification method according to claim 1, characterized in that it comprises the following steps: adding 15ml of toluene and 2ml of methanol into a 100ml reaction bottle, adding 5g of crude sildenafil free base (II), fully stirring, heating to 45-50 ℃, keeping the temperature, stirring for 2h, cooling to room temperature, filtering, and drying to obtain the product (II).
7. A method for detecting sildenafil free base is characterized in that,
the chromatographic conditions were as follows:
A. a chromatographic column: c18Column, Waters Spherisorb ODS 14.6X 250mm 5 μm;
B. mobile phase A: 0.05mol/L triethylamine phosphate solution-methanol-acetonitrile 58: 25: 17;
mobile phase B: 0.05mol/L triethylamine phosphate solution-acetonitrile-30: 70;
C. mobile phase gradient procedure
D. Detection wavelength: 290 nm;
E. column temperature: 30 ℃;
F. sample introduction amount: 20 mu l of the mixture;
G. flow rate: 1 ml/min;
H. operating time: and (5) 60 min.
CN201210581758.XA 2012-12-27 2012-12-27 High-yield purification method for preparation of high-purity sildenafil freebases Active CN102993205B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210581758.XA CN102993205B (en) 2012-12-27 2012-12-27 High-yield purification method for preparation of high-purity sildenafil freebases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210581758.XA CN102993205B (en) 2012-12-27 2012-12-27 High-yield purification method for preparation of high-purity sildenafil freebases

Publications (2)

Publication Number Publication Date
CN102993205A CN102993205A (en) 2013-03-27
CN102993205B true CN102993205B (en) 2015-04-15

Family

ID=47922373

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210581758.XA Active CN102993205B (en) 2012-12-27 2012-12-27 High-yield purification method for preparation of high-purity sildenafil freebases

Country Status (1)

Country Link
CN (1) CN102993205B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105334275B (en) * 2015-12-05 2017-11-10 常州亚邦制药有限公司 A kind of detection method of sildenafil citrate about material
CN107759603B (en) * 2016-08-18 2020-09-01 四川科伦药物研究院有限公司 Preparation method of heterocyclic compound
CN108226354A (en) * 2018-01-02 2018-06-29 上海信谊百路达药业有限公司 A kind of detection method of budesonide residual solvent
CN108558890A (en) * 2018-06-28 2018-09-21 重庆康刻尔制药有限公司 A kind of silaenafil intermediate synthetic method
CN112798719B (en) * 2020-12-29 2023-03-17 植恩生物技术股份有限公司 Detection method of related substance N-methylpiperazine in sildenafil citrate
CN115097026B (en) * 2022-06-08 2023-05-02 河北常山生化药业股份有限公司 Method for detecting pyrazolopyrimidine benzenesulfonate compounds from medicines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
CA2235642C (en) * 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
CN1094492C (en) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 Process for preparing 'Xidinafei' medicine
CN101563348B (en) * 2006-12-21 2011-08-24 上海特化医药科技有限公司 A process for the preparation of sildenafil and the intermediates thereof
CN102690273B (en) * 2012-06-07 2014-11-05 杭州奥默医药技术有限公司 Preparation method of sildenafil

Also Published As

Publication number Publication date
CN102993205A (en) 2013-03-27

Similar Documents

Publication Publication Date Title
CN102993205B (en) High-yield purification method for preparation of high-purity sildenafil freebases
EP3077375B1 (en) Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
EP1513846B1 (en) Process of preparation of olanzapine form i
CN108699068B (en) Preparation method of trifluoromethyl substituted pyran derivative
CN108948020B (en) Refining method of tofacitinib citrate
WO2010045900A1 (en) A method for the preparation of dabigatran and its intermediates
CN109890824B (en) [1,2,4] triazolo [1,5-a ] pyrimidine compounds as PDE2 inhibitors
US8507716B2 (en) Process for preparing pemetrexed disodium and its intermediate, 4-(4-carbomethoxyphenyl) butanal
AU2008320380A1 (en) Novel R,R'-atracurium salts
CN118076586A (en) KIF18A inhibitors
JP5851068B2 (en) Tricyclic compound production method and tricyclic compound obtainable by the production method
JP2008511684A (en) Purification method for anastrozole intermediate
JP2020535193A (en) Process for the preparation of crystalline linagliptin intermediates and linagliptin
CN102850347A (en) Resolution method for pyrazole derivative or salt thereof
CN114773348B (en) Preparation method of midazolam and intermediate thereof
CN111484460B (en) Synthetic method of olanzapine related substance compound I and compound II
JP6748329B1 (en) Crystal form of sofupyronium bromide and method for producing the same
ES2427048T3 (en) A process for producing a pure form of 2-methyl-4- (4-methyl-1-piperazinyl) -10H-thieno [2,3-B] [1,5] benzodiazepine
CN101883486B (en) Process for preparing r-gossypol l-phenylalaninol dienamine
WO2006009374A1 (en) Process for preparing levofloxacin or its hydrate
WO2006008302A2 (en) Improved process for the manufacture of mirtazapine
CN107602518B (en) Coumarin-dithiocarbamate derivative and synthesis method thereof
CN110741006B (en) Process for converting crude ascomycin to purified pimecrolimus
KR101462850B1 (en) Process for the preparation of highly pure entecavir monohydrate
CN114989102B (en) Preparation method of oxazepam

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant